
Brief intro:
- Author: Qingqing Yang, Shunfa Chen, Pengfei Zhang, Zhonghua Lu, Shuwen Chang, Leo E. Wong
- Journal: Journal of Biological Chemistry
- Doi: https://www.doi.org/10.1016/j.jbc.2025.110530
- Publication Date: 2025/7/26
Abstract
α-Synuclein (αSyn) aggregation via liquid-liquid phase separation (LLPS) has recently emerged as a crucial mechanism underlying amyloid fibril formation implicated in Parkinson's disease. However, comprehensive investigation of the physicochemical properties of αSyn condensate remains incomplete. Here, we demonstrate that αSyn condensates exhibit a highly negative electrostatic potential, revealed by preferential enrichment of positively charged fluorophores or fluorophore-labeled αSyn. We further demonstrate that αSyn LLPS is regulated by a balance between self-association and electrostatic repulsion, with excess negative charge inhibiting phase separation. To study αSyn LLPS in a cellular context, we generated a stably transfected SH-SY5Y cell line that forms gel-like, non-toxic αSyn condensates upon differentiation. Most importantly, these intracellular condensates maintain a negative electrostatic potential, as evidenced by mEGFP probes systematically engineered with increasing positive charge. Our findings underscore the central role of electrostatic potential in modulating molecular partitioning within αSyn condensates and suggest that similar electrostatic principles may apply to other biomolecular condensates.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
